Generic Name: azathioprine
Brand Names:
Azasan, Imuran
Special Alerts:
[Posted 04/14/2011] ISSUE: FDA continues to receive reports of a rare cancer of white blood cells (known as Hepatosplenic T-Cell Lymphoma or HSTCL, primarily in adolescents and young adults being treated for Crohn’s disease and ulcerative colitis with medicines known as tumor necrosis factors (TNF) blockers, as well as with azathioprine, and/or mercaptopurine. TNF blockers include infliximab (Remicade), etancercept (Enbrel), adalimumab (Humira), certolizumab pegol (Cimzia) and golimumab (Simponi).
BACKGROUND: HSTCL is an aggressive (fast-growing) cancer and is usually fatal. The majority of cases reported were in patients being treated for Crohn’s disease or ulcerative colitis, but also included a patient being treated for psoriasis and two patients being treated for rheumatoid arthritis. FDA is now updating the number of reported cases of HSTCL.
Although most reported cases of HSTCL occurred in patients treated with a combination of medicines known to suppress the immune system, including the TNF blockers, azathioprine, and/or mercaptopurine, there have been cases reported in patients receiving azathioprine or mercaptopurine alone.
- Educate patients and caregivers about the signs and symptoms of malignancies such as HSTCL so that they are aware of and can seek evaluation and treatment of any signs or symptoms. These may include splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, and weight loss.
- Monitor for the emergence of malignancies when a patient has been treated with TNF blockers, azathioprine, and/or mercaptopurine.
- Know that people with rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis may be more likely to develop lymphoma than the general U.S. population. Therefore, it may be difficult to measure the added risk of TNF blockers, azathioprine, and/or meracaptopurine.
Read the Drug Safety Communications for other specific recommendations for Healthcare Professionals and Patients and the Data Summary for additional information. For more information visit the FDA website at: [Web] and [Web].
 | 50 mg | LOGO 50 mg
bottle, 100 each Azathioprine 50mg, Oral tablet, yellow, oblong-shaped, scored, side 1:50 mg, side 2:LOGO |
 | 54 043 50 mg
box, 10 unit dose blister packs, 10 each Azathioprine 50mg, Oral tablet, yellow, round-shaped, scored, side 1:54 043 |
 | ZC 59 50 mg
bottle, 100 each Azathioprine 50mg, Oral tablet, yellow, round-shaped, scored, side 1:ZC 59 |
 | GG 210 50 mg
bottle, 100 each Azathioprine 50mg, Oral tablet, yellow, oblong-shaped, scored, side 1:GG 210 |
 | A Z 50 mg
bottle, 100 each Azathioprine 50mg, Oral tablet, yellow, faceted edge, round-shaped, scored, side 1:A Z |
 | 50 mg | Z 50 mg
bottle, 100 each Azathioprine 50mg, Oral tablet, yellow, oblong-shaped, scored, side 1:50 mg, side 2:Z |
The Healthline Site, its content, such as text, graphics, images, search results, HealthMaps, Trust Marks,
and other material contained on the Healthline Site ("Content"), its services, and any information or material
posted on the Healthline Site by third parties are provided for informational purposes only. None of the
foregoing is a substitute for professional medical advice, examination, diagnosis, or treatment. Always seek
the advice of a physician or other qualified healthcare provider with any questions you may have regarding a
medical condition. Never disregard professional medical advice or delay in seeking it because of something you
have read on the Healthline Site. If you think you may have a medical emergency, call your doctor or 911 immediately.
Please read the
Terms of Service
for more information regarding use of the Healthline Site.
